Key result
Misfolded sarcoglycans responsible for sarcoglycanopathies could potentially be rescued to the cell membrane by pharmacological agents that assist their maturation along the ER secretory pathway.
The ER quality control machinery represents a potential pharmacological target for rescuing misfolded proteins in sarcoglycanopathies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ER-targeted rescue in sarcoglycanopathies; prospective trials required before clinical consideration.
Sarcoglycanopathies are a group of autosomal recessive muscle-wasting disorders caused by genetic defects in one of four cell membrane glycoproteins, alpha-, beta-, gamma- or delta-sarcoglycan. These four sarcoglycans form a subcomplex that is closely linked to the major dystrophin-associated protein complex, which is essential for membrane integrity during muscle contraction and provides a scaffold for important signalling molecules. Proper assembly, trafficking and targeting of the sarcoglycan complex is of vital importance, and mutations that severely perturb tetramer formation and localisation result in sarcoglycanopathy. Gene defects in one sarcoglycan cause the absence or reduced concentration of the other subunits. Most genetic defects generate mutated proteins that are degraded through the cell's quality control system; however, in many cases, conformational modifications do not affect the function of the protein, yet it is recognised as misfolded and prematurely degraded. Recent evidence shows that misfolded sarcoglycans could be rescued to the cell membrane by assisting their maturation along the ER secretory pathway. This review summarises the etiopathogenesis of sarcoglycanopathies and highlights the quality control machinery as a potential pharmacological target for therapy of these genetic disorders.
No takes yet. Share an insight, caveat, or question.
Sandonà et al. (2009) conducted a review in Sarcoglycanopathies (Limb-girdle muscular dystrophies 2C-2F). Pharmacological interference with ER quality control machinery was evaluated. Misfolded sarcoglycans responsible for sarcoglycanopathies could potentially be rescued to the cell membrane by pharmacological agents that assist their maturation along the ER secretory pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: